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Purpose: To demonstrate the presence of natriuretic peptide receptors (NPRs) in primary human corneal epithelial cells
(p-CEPI),  SV40-immortalized  CEPI  cells  (CEPI-17-CL4)  and  in  human  corneal  epithelium,  and  to  define  the
pharmacology of natriuretic peptide (NP)-induced cGMP accumulation.
Methods:  NPR  presence  was  shown  by  RT–PCR,  western  blot  analysis,  and  indirect  immunofluoresence.  cGMP
accumulation was determined using an enzyme immunoassay.
Results: p-CEPI and CEPI-17-CL4 cells expressed mRNAs for NPR-A and NPR-B. Proteins for both NPRs were present
in these cells and in human corneal epithelium. C-type NP (CNP), atrial NP (ANP) and brain NP (BNP) stimulated the
accumulation of cGMP in a concentration-dependent manner in p-CEPI cells (potency; EC50s): CNP (1–53 amino acids)
EC50=24±5 nM; CNP fragment (32–53 amino acids) EC50=51±8 nM; ANP (1–28 amino acids) EC50=>10 µM; BNP (32
amino acids) EC50>10 µM (all n=3–4). While the NPs were generally more potent in the CEPI-17-CL4 cells than in p-
CEPI cells (n=4–9; p<0.01), the rank order of potency of the peptides was essentially the same in both cell types. Effects
of CNP fragment in p-CEPI and CEPI-17-CL4 cells were potently blocked by HS-142–1, an NPR-B receptor subtype-
selective antagonist (Ki=0.25±0.05 µM in CEPI-CL4–17; Ki=0.44±0.09 µM in p-CEPIs; n=6–7) but less so by an NPR-
A receptor antagonist, isatin (Ki=5.3–7.8 µM, n=3–7).
Conclusions: Our studies showed the presence of NPR-A and NPR-B (mRNAs and protein) in p-CEPI and CEPI-17-CL4
cells and in human corneal epithelial tissue. However, detailed pharmacological studies revealed NPR-B to be the
predominant functionally active receptor in both cell-types whose activation leads to the generation of cGMP. While the
physiologic role(s) of the NP system in corneal function remains to be delineated, our multidisciplinary findings pave the
way for such future investigations.
Atrial natriuretic peptide (ANP) [1] and brain natriuretic
peptide  (BNP)  [2,3]  activate  cytoplasmic  membrane-
spanning receptors which themselves are guanylyl cyclases
(GCs) [4-7]. Three sub-types of receptors (NPR-A, NPR-B,
NPR-C) have been discovered so far that interact with the
natriuretic peptides (NPs) [4-7]. While NPR-A and NPR-B
mediate the effect of the NPs to generate cGMP, NPR-C is a
so-called “clearance receptor” that apparently is not coupled
to an effector system and is involved in eliminating NPs when
the concentrations of the latter exceed a certain level [4-7].
While ANP and BNP selectively activate NPR-A, the C-type
natriuretic  peptide  (CNP)  binds  selectively  and  with  high
affinity and stimulates NPR-B [4-8]. NPs have many diverse
physiologic  functions  in  vascularized  tissues  including
natriuresis, diuresis, vasorelaxation, hormone secretion, and
modulation of neural transmission and Ca2+-channel activity
[4-7]. Furthermore, NPs can affect tissue contractility, and cell
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proliferation  and  differentiation  via  the  cGMP  that  is
generated upon NPR activation [5,9-11].
Overall, the roles of NPs in ocular functions are poorly
defined  especially  in  the  avascular  corneal  epithelium.
However, the presence of immunoreactive ANP has been
reported in the anterior uvea, retina, aqueous humor, ciliary
body, and lacrimal gland [12-15]. NPR-A has been observed
on the epithelial side of the ciliary body [16] and in the retina
[17], while NPR-B has been found in the trabecular meshwork
(TM),  ciliary  muscle  (CM),  and  in  non-pigmented  ciliary
epithelial cell [18]. Topical or intracameral administration of
NPs in rabbits causes a reduction in intraocular pressure (IOP)
[19,20].
The corneal epithelium and the tear film that covers it
represent important barriers to protect the eye from airborne
pathogens, allergens, u.v. light, and chemicals [21]. A clear,
undamaged cornea is of course also important to permit light
entry through to the visual axis for proper vision. Thus, any
damage to the corneal epithelial cells (CEPIs) caused by the
aforementioned  elements  can  result  in  inflammation,
perforation, neovascularization, fibrosis, and scarring that can
seriously reduce visual acuity and cause partial or complete
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1241blindness [21]. Therefore, it is important to better understand
the physiology, pharmacology and pathology of the corneal
surface  and  the  resident  CEPIs.  Relative  to  NPs  and  the
cornea, the locally released and/or lacrimal gland-derived NPs
may influence the CEPIs upon their arrival in the tear film.
Accordingly, while NPR-C, the clearance receptor, was found
on the bovine corneal endothelium [22], a GC-coupled NPR-
B was identified in total homogenates of whole bovine corneas
where  CNP  was  twice  as  potent  at  stimulating  cGMP
production as ANP [23]. However, the cell-type(s) responsive
to the NPs in the whole corneal tissue homogenates was not
elucidated [23]. Likewise, even though ANP inhibited the
epidermal growth factor-induced cell proliferation in rabbit
corneal  epithelial  cell  cultures  via  an  NPR-A  [24],
unfortunately other NP agonists (e.g., CNP) were not used by
these investigators to define the pharmacological specificity
of  the  NPRs  present  in  the  rabbit  CEPI  cells  [24].
Consequently, there is poor understanding about the NPR
system in the cornea, especially that of humans, and especially
that  of  the  CEPIs.  The  fact  that  the  CEPIs  are  probably
important in mediating the effects of locally produced NPs
and/or those released from the lacrimal gland [17] underscores
the need to better define the presence of and to characterize
the pharmacology of functionally active NPRs on the human
CEPIs. The results from such studies may reveal important
new means to positively influence corneal epithelial health
and  may  lead  to  discovery  of  new  therapeutic  agents  to
promote  corneal  wound  healing  and/or  treat  dry  eye  and
related disorders. Therefore, the aims of our studies were to
demonstrate  the  presence  of  NPRs  in  the  human  corneal
epithelium, primary human corneal epithelial (p-CEPI) cells,
and in a human corneal epithelial cell-line (CEPI-17-CL4)
[25-28]  at  the  mRNA  and  protein  levels.  We  further
characterized,  functionally  and  pharmacologically,  the
predominant NPR present in p-CEPI and CEPI-17-CL4 cells
using a range of agonists and antagonists and measurement of
cGMP production.
METHODS
Materials: Sources of materials, reagents, equipment used
were as follows: NPs from American peptide (Vista, CA) or
Bachem (San Carlos, CA); various other compounds from
either Sigma-Aldrich (St. Louis, MO), Tocris (Ellisville, MO)
or  Biomol  (Plymouth  Meeting,  PA);  HS-142–1  was  a
generous gift from Kyowa Hakko Co. (Tokyo, Japan); RT–
PCR  materials  from  InVitrogen  (San  Diego,  CA);  Gel
electrophoresis materials from Gibco BRL (Carlsbad, CA)
and  New  England  Biolabs  (Ipswich,  MA);
Immunocytochemicals  from  Molecular  Probes  (Portland,
OR),  Calbiochem  (La  Jolla,  CA),  and  Fisher  Scientific
(Pittsburgh, PA); NPR antibodies from Abcam (Cambridge,
UK);  western  blot  materials  from  Pierce  (Rockford,  IL),
Sigma-Aldrich or Amersham Biosciences (Buckinghamshire,
UK).;  Enzyme  immunoassay  kits  from  Amersham
(Piscataway, NJ); Cell culture reagents and materials from BD
Biosciences (San Jose, CA), Cascade Biologicals (Portland,
OR), Gibco BRL, or Sigma-Aldrich. All tissues were obtained
in  compliance  with  good  clinical  practices  with  informed
consent under institutional review board regulations and with
the tenets of the Declaration of Helsinki.
Cell Culture:
Corneal Epithelial Cells (p-CEPI and CEPI-17-CL4)
—Epithelial sheets were obtained from Eye Bank corneas
from ocular pathogen-free donors (aged 40–86 years) and the
primary  cells  cultured  as  previously  described  [25-28].
Briefly, after incubation of corneas at 4 °C for 48 h in dispase
(diluted with calcium free EpiLife® medium to 12 Units/ml),
the  epithelial  sheets  were  removed  from  the  stromas,
dissociated  into  single  cell  suspension,  and  plated  on  to
murine-collagen-IV-coated tissue culture flasks (75 cm2). The
cells were cultured in EpiLife® (Cascade Biologics Invitrogen,
Carlsbad, CA), a serum free defined media containing human
corneal growth supplement, to 80% confluence. The cells
were  sub-cultured  by  harvesting  with  trypsin  /  EDTA,
treatment  with  trypsin  inhibitor  and  plating  into  murine-
collagen-IV-coated multi-well plates.
The generation and extensive characterization of simian
virus  (SV)-40  immortalized  human  p-CEPI  cells  (clone
CEPI-17-CL4)  has  been  previously  documented  [25-28].
CEPI-17-CL4  cells  (passages  58–158)  were  cultured  and
plated into multi-well plates as described above for p-CEPI.
PCR: RNA was isolated using Trizol® reagent according to
manufacturer’s  recommendations.  Medium  free  cell
monolayers were treated with Trizol® (1ml / cm2) and the cells
detached from the flask using a cell scraper. After transferring
the mixture to centrifuge tubes (1 ml), and incubation at 30 °C
for 5 min, choloroform was added (0.2 ml) and the closed
tubes shaken vigorously for 15 s, then opened and incubated
at 30 °C for 2–3 min. The samples were centrifuged at 12,000×
g (2–8 °C) for 15 min and the top aqueous layer carefully
transferred  to  a  fresh  centrifuge  tube.  The  RNA  was
precipitated with isopropanol (0.5 ml/ml of Trizol® reagent)
and the precipitate washed twice with ethanol and finally
dissolved in DEPC- treated water. Primers were designed
using Primer 3 Input (Version 0.4.0) and cross-checked using
nucleotide BLAST and were: NPR-A forward: 5′-GCA TTG
AGC TGA CAC GAA AA-3′; reverse: 5′-GTC CAG GGT
GAT GCT CTC AT-3′; NPR-B forward: 5′-GGC ACA GGA
ATC ACC TTC AT-3′; reverse: 5′-GGT GTT GGC AAA
GAT CTG GT-3′. The RT–PCR kit reaction mixture consisted
of the following: RNA sample 1 µg, PCR buffer (2 reaction
mix from the kit) 25 µl, forward primer 2 µl (10 µM stock),
reverse primer 2 µl (10 µM stock), reverse transcriptase with
Taq polymerase 2 µl, and DNase-free water to make total
volume 50 µl. The reaction was run for 30 cycles according
to  manufacturer’s  recommendation  and  using  annealing
temperature (Ta) of 55 °C. cDNA synthesis was performed by
incubation at 50 °C for 15 min followed by 94 °C for 2 min.
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30 s, Step 3: Ta for 30 s, Step 4: 72 °C for 1 min, Step 5: Repeat
Steps 2–4 for 30 cycles, Step 6: 72 °C for 5 min, Step 7: 4 °C
storage until needed.
Agarose  gel  electrophoresis:  Agarose  gel  (1.2%)  was
prepared by heating agarose in TAE buffer. After cooling,
ethidium bromide (6 μl in 100 ml of solution) was added to
the  mixture  and  the  gels  cast  in  a  Horizon  58  (Life
Technologies,  Carlsbad,  CA)  apparatus.  The  total  sample
obtained from PCR was loaded on to the gel with 5 μl of
bromophenol blue dye and 100 bp ladder in two lanes flanking
the samples. Electrophoresis was performed at 100 V until the
dye reached half the length of the gel.
Indirect immunofluorescence:
Corneal  tissue  immunohistochemistry—Donor
corneas  were  fixed  in  4%  formaldehyde  (4  °C,  24  h),
dehydrated through a series of ethanol and xylene incubations,
and embedded in paraffin. Embedded tissue was sectioned and
the  paraffin  removed  from  the  sections  (~10  µm)  by
incubations in xylenes and ethanols. After re-hydration (30
min) in PBS (0.256 g/l NaH2PO4 H2O, 1.19 g/l Na2HPO4, 8.76
g/l NaCl, pH 7.4), and distilled water washes (3×5 min), the
tissue sections were blocked overnight at 4 °C in PBS + 1%
BSA +1% horse serum. The tissue sections were then rinsed
with PBS and distilled water (3×5 min), and incubated with
primary (1°) antibody at 4 °C, overnight and rinsed in PBS
(3×10 min) containing Tween-20 (0.1%). The tissue sections
were then incubated with secondary (2°) antibody (1 h, at
room temperature) and rinsed in PBS containing Tween-20
(0.1%, 3×10 min). The specimens were rinsed in PBS (3×10
min), distilled water (3×10 min), stained with 4’,6-diamino-2-
phenylindole (DAPI, 220 nM, 10 min) and were mounted
using FluorSave™ (Calbiochem, La Jolla, CA).
Cellular  immunocytochemistry—Approximately
15,000 cells were plated on glass coverslips and cultured in
EpiLife® (Cascade Biologics Invitrogen). When the cultures
had stabilized, the coverslips were rinsed in PBS and fixed in
neutral formalin (4% in PBS, overnight at 4 °C). After re-
hydration  in  phosphate  buffered  saline  (PBS,  0.256  g/l
NaH2PO4 H2O, 1.19 g/l Na2HPO4, 8.76 g/l NaCl, pH 7.4; for
30  min)  and  distilled  water  washes  (3×),  the  cells  were
blocked (overnight at 4 °C) in PBS + 1% BSA (BSA). The
cells were then rinsed with PBS and distilled water (3×) and
incubated with 1° antibody diluted in PBS at 4 °C overnight.
After rinsing in PBS, containing Tween-20 (0.1%; 3×10 min),
cells were incubated with 2° antibody at room temperature
(RT, 1.5 h) and rinsed in PBS + Tween-20 (0.1%, 3×10 min).
The specimens were rinsed in PBS (3×10 min), distilled water
(30 min), stained with DAPI (200nm, 10 min) and mounted
on glass slides (FluorSave™).
Antibodies  and  image  acquisition:  Primary  antibodies  for
NPR-A and NPR-B were used at 1:100 dilution. Conjugated
Alexa Fluor 594 nm goat anti-rabbit was used as the secondary
antibody at a concentration of 6 mg/ml of 1% BSA; secondary
antibodies were used at dilutions of 1:1,000. Negative controls
in all experiments were specimens labeled with 2° antibody
only and DAPI to show nuclei. Mounted specimens were
examined on Olympus AX70 (Olympus America, Inc., Center
Valley,  PA,)  fluorescent  microscope  using  SPOT  Twain
software (Microsoft, Issaquah, WA).
Western blot analysis: Cells were cultured as described above
and when near confluent were washed with PBS and treated
with lysis buffer (300 μl, 2.5 ml of 1 M TRIS buffer [pH 7.0],
1 g SDS, 2.5 g sucrose in 50 ml of distilled water) for 5 min
at  room  temperature.  The  genomic  DNA  was  sheared  by
several passes through a 22 gauge needle and samples were
stored  at  −20  °C  until  needed.  BCA  (bicinchoninic  acid)
protein  assays  (Pierce,  Rockford,  IL)  were  performed  to
determine protein concentrations and to ensure equal loading
of lanes. Protein lysates were mixed with 3 μl of loading buffer
and heat denatured for 5 min. Protein (30 μg) was loaded in
each lane of the denaturing SDS–PAGE (12% separating and
4% stacking), which was run at 150 V with Tris/glycine as the
running  buffer.  Protein  bands  were  transferred  on  to  the
nitrocellulose membrane (VWR International, Irving, TX) by
electro-blotting overnight (4 °C) at 10 V in Tris/Glycine buffer
with 20% methanol and confirming the transfer with Ponceau
Red of the membranes. After de-staining in distilled water the
membranes were incubated in blocking buffer (5% powdered
milk and 1% BSA in PBS) for 3 h at room temperature.
Membranes  were  then  incubated  for  30  min  (RT),  then
overnight (4 °C), and finally the following morning for 30 min
(RT) with primary antibodies against NPR-A and NPR-B
diluted  to  1:1,500  and  1:3,000,  respectively,  in  PBS
containing 0.1% Tween-20 (PBST) on a plate rocker. After
rinsing in PBST containing 0.1% Tween-20 (3×10 min), the
membranes were incubated with 2° antibody (anti rabbit IgG
from  donkey  HRP  conjugated)  dissolved  at  a  dilution  of
1:1,000 in PBST, for 1.5 h (RT). After washing with PBST
3×10  min,  the  membranes  were  developed  by  ECL  (GE
Healthcare, Piscataway, NJ) chemiluminescence.
Measurement of GC activity in cultured cells: Cells were
seeded in 48 wells plates and upon reaching confluence they
were rinsed twice with 0.5 ml Dulbeco’s modified Eagle’s
medium (DMEM)/F-12. Cells were then pre-incubated for 20
min in the presence or absence of both NPR-A or NPR-B
antagonists  in  DMEM/F-12  containing  1.0  mM  of  the
phosphodiesterase  inhibitor  3-isobutyl-1-methylxanthine
(IBMX) at 23 °C. NPs were added at the end of this period,
and the reaction was allowed to proceed for another 15 min at
23 °C. After aspiration of the medium, ice-cold 0.1 M acetic
acid  (150  μl,  pH  3.5)  was  added  to  each  well  for  the
termination of cGMP synthesis and cell lysis. Finally, ice-cold
0.1 M sodium acetate (220 μl, pH 11.5–12.0) was added to
neutralize the samples before analysis of cGMP produced by
an enzyme immunoassay kit (Amersham, Piscataway, NJ) as
recommended  by  the  manufacturer  and  as  previously
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tissues/cell-types [20,29-31].
RESULTS
RT–PCR: mRNAs for NPR-A and NPR-B were shown to be
present in both p-CEPI and CEPI-17-CL4 cells (Figure 1).
Immunohisto-  and  immunocyto-  chemistry:  Expression  of
NPR-A and NPR-B was observed in the epithelium of human
corneas and was particularly strong in the superficial layers
of the central region (Figure 2A-D). NPR-B appeared to be
expressed more strongly than NPR-A in the epithelium of the
limbus  and  the  expression  of  both  was  confined  to  the
superficial layers. Similarly, immunocytochemical analysis of
the  cultured  cell  monolayers  showed  what  appeared  be
cytoplasmic expression of both NPR-A and NPR-B (Figure
3).
Western blot analysis: Cellular NPR-A and NPR-B protein
expression was confirmed by western blot analysis of p-CEPI
and CEPI-17-CL4 cell lysates (Figure 4A,B). Some donor
variability was observed in the levels expressed by p-CEPI
cells. After normalization of expression to the house-keeping
enzyme  gene  (glycerol-3-phosphate  dehydrogenase;
GAPDH), CEPI-17-CL4 cells were shown to have a higher
expression of NPR-B than p-CEPI cells (p<0.05), while the
latter cells had a higher expression of NPR-A than CEPI-17-
CL4 cells though this did not reach statistical significance
(p<0.1; Figure 4C). In addition, CEPI-17-CL4 cells expressed
a greater amount of NPR-B than the p-CEPI cells (p<0.05) but
this could have been a reflection of greater variability in the
isolated cells from human donor eyes.
Pharmacological characterization of NPRs in CEPI Cells: In
the presence of IBMX, activation of GC in the ocular cells by
NPs resulted in cGMP accumulation. Time-course studies
with CNP fragment (1 μM) revealed that for up to 25 min there
was a linear increase of cGMP production with a good signal-
to-noise  ratio  (Figure  5A).  For  convenience,  a  15  min
stimulation  time  point  was  then  applied  to  all  other
pharmacological studies.
CNP,  CNP  fragment,  BNP,  and  ANP  stimulated  the
production of cGMP in CEPI-17-CL4 cells in a concentration-
dependent manner with the first two peptides causing the
highest accumulation of cGMP (Figure 5B; Table 1). ANP
and BNP behaved as partial agonists relative to CNP and the
CNP fragment. The basal level of cGMP in cell lysates was
24±5 fmol/well (mean±SEM, n=24). Incubation of the cells
with 10 μM ANP for 15 min increased the accumulation of
cGMP  sevenfold  to  160±31  fmol/well  (n=4).  The
concentration-response  curves  for  ANP  yielded  apparent
potency  (EC50)  of  97±25  nM  (n=4)  in  these  cells.  The
stimulatory effect of BNP was 23 fold above the basal level,
with EC50s of 203±95 nM (n=4). In contrast, NPR-B receptor
subtype-selective agonist CNP, increased the accumulation of
cGMP 53 fold above the basal level to 1,271±133 fmol/well
(n=6) with EC50s of 7±2 nM (n=8). A 22-amino acid fragment
of CNP (CNP-F) increased the level of cGMP 47 fold above
the basal level to 1,135±96 fmol/well (n=5) with EC50s of
16±2 nM (n=5). The various NPs tested were all significantly
more potent (p<0.01) in the CEPI-17-CL4 cells than in the p-
CEPI cells (Table 1).
NPs  were  also  effective  in  increasing  cGMP
accumulation in p-CEPI, and as in the CEPI-17-CL4 cells, the
most efficacious and potent NPs were CNP and CNP fragment
(Figure 5C). The basal level of cGMP in p-CEPI cells was
7.8±1.5 (mean±SEM, n=10). Treatment of the p-CEPI cells
with 10 µM ANP increased the cGMP level threefold above
basal to 26±1 fmol/well (n=3). BNP was not as potent as ANP
and  its  maximal  stimulation  resulted  in  31±1.5  fmol/well
(n=3) of cGMP. The EC50 of both ANP and BNP peptides was
>10,000  nM.  Again,  in  contrast  with  ANP  and  BNP  and
similar to it’s effect in CEPI-17-CL4 cells, CNP, the NPR-B
selective agonist was much more potent than ANP with the
mean EC50s of 24±5 nM (n=4) and 27 times more efficacious
than ANP yielding cGMP levels of 690±68 fmol/well (n=3).
CNP fragment was as efficacious as CNP and it increased the
accumulation  of  cGMP  to  664±83  fmol/well  (n=3)  with
EC50s of 51±8 nM. As for CEPI-17-CL4 cells above, the
pharmacological profiles of these compounds suggested that
NPR-B was also the most prominent subtype of NPR in p-
CEPI cells (Figure 5C; Table 1).
Figure 1. Detection of NPR-A and NPR-B mRNAs in human p-CEPI and CEPI-17-CL4 cells by RT–PCR. Lanes 1 and 2: NPR-A in human
p-CEPI cells (donor ages 64 and 81); Lane 3: NPR-A in human CEPI-17-CL4 cells. The PCR product for NPR-A is equal to 179 bp. Lane 4:
NPR-B in human CEPI-17-CL4 cells. The PCR product for NPR-B is equal to 237 bp. Lanes 5 and 6: NPR-B in human p-CEPI cells (donor
ages 64 and 81).
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1244Figure  2.  Expression  of  NPR-A  and  NPR-B  in  paraffin  sections  of  formalin-fixed  human  corneas  as  determined  by  indirect
immunofluorescence. A, B: The presence of NPR-A in the epithelium of the central cornea. A shows stronger expression in the superficial
layers when compared with the control (B). C, D: C shows the presence of NPR-A primarily in the superficial layers of the limbal epithelium.
The control shows no expression (D). E, F: E shows strong expression of NPR-B primarily in the superficial cell layers of the central cornea
compared when compared with the control (F). G, H: G shows that NPR-B is very distinctly confined to the superficial epithelium of the
limbus compared with the control (H). All panels are at 10× magnification.
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NPRs  in  the  CEPI  cells,  HS-142–1  was  evaluated  for  its
antagonist activity. HS-142–1 inhibited CNP-induced cGMP
production  in  a  concentration-dependent  manner  with  the
inhibitory potency (Ki) of 0.25±0.05 µM (n=6) in CEPI-17-
CL4 (Figure 6), and with a Ki value of 0.44±0.09 µM (n=7)
Figure 3. The expression of NPR-A and NPR-B in formalin-fixed human p-CEPI and CEPI-17-CL4 cells by indirect immunofluorescence is
shown. A shows a strong expression of NPR-A in human p-CEPI cells, while B shows expression of NPR-A in CEPI-17-CL4 cells. C shows
expression of NPR-B in human p-CEPI cells while D shows expression of NPR-B in CEPI-17-CL4 cells. E and F are DAPI labeled controls
(treated with secondary antibody only) for human p-CEPI and CEPI-17-CL4 cells, respectively. Each panel is at 40× magnification.
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types (p<0.1). Isatin (indole-2,3 dione), an NPR-A receptor
antagonist,  partially  inhibited  CNP-induced  cGMP
production,  and  was  less  potent  (Ki=5.3±1.7  µM;  n=7  in
CEPI-17-CL4, and Ki=7.8±4.5 µM; n=3 in p-CEPI cells) than
HS-142–1 (Figure 6).
DISCUSSION
As described in the Introduction, diseases or injuries of the
corneal epithelium compromise its functions and can, if left
untreated, result in loss of visual acuity and impair vision
[21,25]. For these and other reasons, we and others have been
involved in the study of ocular surface tissues and cells [21,
25-28,30,32-39].
Figure  4.  Expression  of  NPR-A  and
NPR-B  in  human  p-CEPI  cells  and
CEPI-17-CL4  cells  as  determined  by
western blot analysis. A: The presence
of NPR-A protein (band observed at 40–
55 kDa) in CEPI-17-CL4 and in human
p-CEPI cells (from 56, 53, and 56 year
old donors) is shown. B: The presence
of  NPR-B  protein  (band  observed  at
24  kDa)  is  shown  for  three  different
donors of human p-CEPI cells (ages 40,
53, and 56) cells and in CEPI-17-CL4
cells. C: The expression of NPR-A and
NPR-B in human p-CEPI and CEPI-17-
CL4 cells was normalized to GAPDH.
The  figure  shows  an  apparent  lower
expression of NPR-A in CEPI-17-CL4
cells  than  in  human  p-CEPI  cells
(p<0.1); the expression of NPR-B was
higher  in  CEPI-17-CL4  than  that  in
human  p-CEPI  cells  (p<0.05).  The
NPR-B  expression  was  greater  than
NPR-A  expression  in  CEPI-17-CL4
cells  (p<0.05).  However,  the  both
receptor subtypes were expressed to the
same extent in the p-CEPI cells (p<0.1).
Figure 5. A: Time-course of increase in cGMP induced by CNP fragment in CEPI-17-CL4 cells is shown. Cyclic GMP concentration was
measured after the cells were treated with CNP fragment for the indicated period. Each symbol represents a single datum point determined in
duplicate. B and C: Effects of NPs on cGMP production in human p-CEPI and CEPI-17-CL4 cells are shown. Cyclic GMP concentration was
measured after the cells were treated with the indicated concentrations of various NPs for 15 min. Each symbol represents a single datum
point determined in duplicate. Results were obtained in 4 independent studies for CEPI-17-CL4 cells (B) and 3 independent studies for human
p-CEPI cells (C).
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1247Various  pharmacologically  important  peptides  and
proteins have been evaluated in the cornea and it is becoming
clear that in spite of its avascularity the corneal epithelium
responds to endogenous (from paracrine/ autocrine sources)
and  exogenous  biologically  active  peptides  and  cytokines
[23,26,27]. The presence of the natriuretic family of peptides
and their receptors have not been previously documented in
the human cornea. Since some of the functions of this peptide
family  have  been  implicated  in  cell  proliferation  and
differentiation [5-7,24], which are the essential events in the
homeostasis and repair of the corneal epithelium [40], we
undertook the present study to demonstrate that their presence
might  also  be  of  physiologic  and  pharmacological
significance. We first showed the presence of mRNAs for
NPR-A  and  NPR-B  indicating  that  in  monolayer  cellular
model of corneal epithelium (p-CEPI and CEPI-17-CL4 cells)
the genes are actively involved in the transcription process in
the cornea and that the cell-line CEPI-17-CL4 could be a good
model  for  in  vitro  cellular  studies.  Examination  of  tissue
sections of the human cornea showed that the epithelium is a
target for the NPs and that the NPR expression favors the
superficial epithelial cell layers, particularly in the limbus.
This seems reasonable since the tear film compartment is
known to harbor a variety of bioactive peptides [25,27,41] and
the  ocular  surface  includes  the  conjunctiva,  which  is  a
particular site for allergic and inflammatory reactions [26,
27,36,37,41-43]. The presence of NPR-A and NPR-B was
also  shown  by  immunocytochemistry  in  p-CEPI  and
CEPI-17-CL4 cells and confirmed by western blot protein
analysis. Although there was some donor variability in the
expression of NPR-A and NPR-B by p-CEPI cells, it was
interesting  to  observe  that  while  p-CEPI  cells  expressed
higher levels of NPR-A, CEPI-17-CL4 cells favored NPR-B
expression. This difference suggests that as a prelude to in
vivo  studies  it  is  worthwhile  to  be  aware  of  the  possible
differences in responses between cell-line cells and primary
cells [26]. Thus, as it is demonstrated here, it is prudent to
include primary human cells in a multi-disciplinary approach
to  studies  of  pharmacologically  active  agents  [25-28].
Irrespective  of  the  immunocytochemical  observations,
however,  the  pharmacological  data  coupled  with  the
[cGMP]i  production-response  data  indicated  that  the
functionally active subtype of the NPRs was the NPR-B in
both the p-CEPI and CEPI-17-CL4 cells. The apparent lower
expression level of NPR-A may have accounted for such a
difference in CEPI-17-CL4 cells (Figure 4B), however NPR-
B still functionally predominated in the p-CEPI cells where
the expression levels of NPR-A and NPR-B were very similar
(Figure 4B). Another interesting difference between the cell-
types was the fact that the various NPs studied currently were
more potent in the immortalized cells than in the p-CEPI cells
(Table 1; Figure 5B,C). This could be explained by the relative
homogeneity of the cell-line cell population, as compared the
TABLE 1. RELATIVE POTENCIES AND INTRINSIC ACTIVITIES OF VARIOUS NPS FOR THEIR ABILITY TO STIMULATE CGMP PRODUCTION IN HUMAN CEPI
CELLS COMPARED WITH OTHER HUMAN OCULAR CELL-TYPES.
Natriuretic peptide Potency (nM) and
intrinsic activity
(Emax) in p-CEPI
Cells
Potency (nM) and
intrinsic activity (Emax)
in CEPI-17-CL4 Cells
Potency in h-CM
cells (nM)#
Potency in h-
TM16 cells (nM)#
Potency in h-TM3
cells (nM)#
CNP (1–53 amino acids)
EC50 (nM) 24 ± 5 nM 7 ± 2 nM** 19 nM 10 nM 64 nM
Max. effect (%) 100% 100%      
CNP fragment (32–53 amino acids)
EC50 (nM) 51 ± 8 nM 16 ± 2 nM** nd nd nd
Max. effect (%) 96% 89%      
BNP (32 amino acids)
EC50 (nM) >10,000 nM 203 ± 95 nM** 35 nM 75 nM 398 nM
Max. effect (%) 4.5% 43%      
ANP (1–28 amino acids)
EC50 (nM) >10,000 nM 97 ± 25 nM** 102 nM 102 nM 478 nM
Max. effect (%) 3.8% 13%      
Concentration-response curves were generated for each of the NPs shown above using 6 concentrations of each peptide in each
experiment as shown in Figure 5B,C. Data shown above are mean±SEM from 3 to 4 experiments for human p-CEPI cells and
from 4 to 9 experiments for CEPI-17-CL4 cells. #=data from [18] for comparison. h-CM=human ciliary muscle cells; h-
TM=human trabecular meshwork cells; nd=not determined. **=p<0.01 relative to potency in p-CEPI cells by Student’s unpaired
t-test.
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1248heterogeneity  of  the  isolated  primary  cells  from  various
human donor eyes.
Exposure of p-CEPI and CEPI-17-CL4 cells to various
NPs  resulted  in  a  concentration-dependent  increase  in
[cGMP]i indicating that these cells have the ability to translate
the  mRNAs  for  NPRs  into  functionally  active  receptor
proteins.  These  results  further  supported  the  molecular
biologic and immunocytochemical data discussed above. In
view of the fact that CNP and CNP fragment exhibited the
highest  potencies  and  intrinsic  activities  in  elevating
[cGMP]i in p-CEPI and CEPI-17-CL4 cells, with both ANP
and BNP being much weaker, these findings indicated an
NPR-B pharmacology signature as previously documented
for cells derived from other tissues, including human TM and
CM cells [18]. Interestingly, the rank order and potency values
of CNP, BNP, and ANP in the current studies matched well
with those reported for h-CM and h-TM cells (Table 1) [18].
The  fact  that  the  agonist  activity  of  CNP  fragment  was
relatively potently blocked by the NPR-B selective antagonist,
HS-142–1 [44-46], and weakly by isatin [47-49], an NPR-A
antagonist, confirmed the identity of the predominantly active
GC-activating NPR in p-CEPI and CEPI-17-CL4 cell-types
as the NPR-B sub-type. Additionally, the inhibitory potency
of HS-142–1 in these cells (Ki=0.25–0.44 µM) for blocking
the  CNP  fragment-induced  [cGMP]i  generation  compared
well with its reported antagonist potency in numerous other
organ-derived cells-types (Ki=0.33–6.6 µM) [44-46]. Even
though isatin yielded a partial inhibition of CNP fragment-
induced [cGMP]i production in the CEPI cells, its potency was
similar to that previously reported for its inhibitory activity in
non-ocular cell-types (Ki=0.4 µM) [47-49]. Taken together,
the pharmacological profile of the NP agonist and antagonist
activities confirmed the predominance of a functionally active
NPR-B receptor sub-type in p-CEPI and CEPI-17-CL4 cells.
Even though it is now clear from our current studies that
CNP-sensitive NPR-B receptors are present on both p-CEPI
Figure 6. Inhibition of CNP fragment-
induced cGMP production in CEPI-17-
CL4  cells  by  two  NP  receptor
antagonists  is  shown.  The  effects  of
HS-142–1  (10  nM  to  10  µM;  closed
square  symbols)  and  isatin  (0.3–100
µM;  open  circle  symbols)  on  CNP
fragment  (30  nM)-induced  cGMP
generation  were  determined  as
described in the methods section. Data
are mean±SEM from 6 to 7 experiments
for HS-142–1, and from 7 experiments
for isatin. Similar results were obtained
using  p-CEPI  cells.  The  antagonist
potencies of the two compounds in the
two  cell-types  are  provided  in  the
Results section.
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1249and  CEPI-17-CL4  cells  and  in  the  intact  human  corneal
epithelium,  the  potential  physiologic  relevance  of  these
findings  have  not  been  fully  explored  and  warrant  future
investigation. However, the fact that NPs are potent regulatory
mediators of secretory activity [5-7,50] in many epithelial
cell-types  of  the  body,  for  instance  leading  to  chloride
secretion [50], suggests that CNP may modulate electrolyte
composition  of  the  tear  film  on  the  ocular  surface  by
influencing the activity of the NPR-B on the CEPI cells. Since
CNP upregulates aquaporin-4 [51], the water content of the
tear  film  may  be  directly  regulated  by  corneal  NPR-B
receptors. These combined effects of CNP on the corneal cells
in vivo may then regulate water and ion homeostasis [51,52]
on the ocular surface to maintain a stable environment for the
cornea  and  surrounding  tissues.  Furthermore,  since  CNP
inhibits  leukocyte  recruitment  and  platelet-leukocyte
interactions [53], the NPR-B receptors may participate in anti-
inflammatory effects of CNP on the ocular surface [53]. The
involvement  of  NP  system  in  cell  proliferation  [4-7,24]
necessary for corneal wound healing [40] is also possible even
though ANP apparently inhibited cell proliferation induced by
epidermal growth factor (EGF) via the NPR-A subtype [24].
Unfortunately, the latter authors did not study the effects of
CNP on rabbit CEPI proliferation and thus the role of NPR-B
in  this  process  remains  undefined  [24].  Our  preliminary
studies have revealed that CNP fragment neither alone or in
combination with EGF or HS-142–1 influences CEPI cell
proliferation (data not shown) indicating that in human CEPI
cells NPR-B appear not to be involved in modulating cellular
growth.
Corneal epithelial cells, akin to other ocular epithelia
[52],  express  numerous  ion-channels  and  a  multitude  of
receptors [25-28]. Since CNP increases cGMP via NPR-B, as
does carbon monoxide but via a soluble GC [54], and CNP
alters  intracellular  pH  [55],  the  activation  of  K+-channels
[54] and inhibition of Na-K-ATPase [56] of the CEPI cells
may be also affected. The solitary or combined effects of
CNP’s activation of NPR-B to produce [cGMP]i may thus
have profound effects on the physiologic functions of the
corneal  epithelial  cells  [40,50-57],  including  possible
homeostatic regulation of ocular surface osmolarity and/or
cell volume, and/or acting as mitochondrial protective agents
as it pertains to other ocular tissues [58].
In conclusion, a multidisciplinary approach allowed us to
probe the molecular biology and biochemical pharmacology
of the NPR system in the human corneal epithelium at the
cellular and tissue levels. Compelling data are presented here
that indicate the predominance of NPR-B whose activation
leads to the generation of [cGMP]i. The agonist profile of
activity of NPs in p-CEPI and CEPI-17-CL4 cells, coupled
with  the  antagonist  profile  obtained  using  HS-142–1  and
isatin,  supported  the  immunohistochemical  findings.  It  is
hoped  that  our  collective  data  will  stimulate  further
investigations into determining the physiologic roles of the
NPR system in the human and animal corneal epithelium.
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